Denosumab
- Generic Name
- Denosumab
- Brand Names
- Prolia, Xgeva, Wyost, Jubbonti
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 615258-40-7
- Unique Ingredient Identifier
- 4EQZ6YO2HI
- Background
Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption markers in patients with a variety of metastatic tumors and is being investigated in multiple clinical trials for the prevention and treatment of bone metastases. Chemically, it consists of 2 heavy and...
- Indication
Prolia is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture. It reduces the incidence of vertebral, nonvertebral, and hip fractures. Prolia is also indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer. It can also be use...
- Associated Conditions
- Bone Fractures, Bone Giant Cell Tumor, Bone Loss, Bone pain, Spinal Cord Compression, Bone destruction, High risk of fracture Osteoporosis, Refractory Hypercalcemia of malignancy
- Associated Therapies
- -
Effect of RANKL Inhibition on UV-induced Immunosuppression
- First Posted Date
- 2013-11-07
- Last Posted Date
- 2014-07-24
- Lead Sponsor
- Innovaderm Research Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT01978483
- Locations
- 🇨🇦
Innovaderm Research Inc., Montreal, Quebec, Canada
AMG 162 (Denosumab) Phase 3 Study (DESIRABLE Study) in Participants With Rheumatoid Arthritis on Disease-modifying Antirheumatic Drugs (DMARDs) Treatment
- First Posted Date
- 2013-10-31
- Last Posted Date
- 2020-02-12
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 679
- Registration Number
- NCT01973569
Denosumab for Breast Cancer With Bone Mets
- First Posted Date
- 2013-09-27
- Last Posted Date
- 2019-11-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 7
- Registration Number
- NCT01952054
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-09-26
- Last Posted Date
- 2021-10-25
- Lead Sponsor
- Amgen
- Target Recruit Count
- 226
- Registration Number
- NCT01951586
- Locations
- 🇬🇧
Research Site, Preston, United Kingdom
A Study to Evaluate Denosumab in Young Patients With Primary Breast Cancer
- First Posted Date
- 2013-05-30
- Last Posted Date
- 2018-11-27
- Lead Sponsor
- Jules Bordet Institute
- Target Recruit Count
- 27
- Registration Number
- NCT01864798
- Locations
- 🇦🇺
Royal Melbourne Hospital, Victoria, Australia
🇧🇪Institute Jules Bordet, Brussels, Belgium
🇧🇪Hopital Erasme, Brussels, Belgium
Translational Therapy in Patients With Osteogenesis Imperfecta - A Pilot Trial on Treatment With the Rankl-Antibody Denosumab
- First Posted Date
- 2013-02-27
- Last Posted Date
- 2015-01-27
- Lead Sponsor
- University of Cologne
- Target Recruit Count
- 10
- Registration Number
- NCT01799798
- Locations
- 🇩🇪
University Cologne, Childrens Hospital, Cologne, Germany, Cologne, NRW, Germany
RA Denosumab on Bone Microstructure Study
- First Posted Date
- 2013-01-17
- Last Posted Date
- 2014-09-11
- Lead Sponsor
- Chinese University of Hong Kong
- Target Recruit Count
- 40
- Registration Number
- NCT01770106
- Locations
- 🇭🇰
Prince of Wales Hospital, Shatin, N.t., Hong Kong
Effects of Teriparatide or Denosumab on Bone in Postmenopausal Women With Osteoporosis
- Conditions
- Interventions
- First Posted Date
- 2012-12-20
- Last Posted Date
- 2015-10-08
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 69
- Registration Number
- NCT01753856
- Locations
- 🇨🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sainte-Foy, Quebec, Canada
Treatment of Atraumatic Bone Marrow Edema With Denosumab and Teriparatide vs Placebo
- Conditions
- Interventions
- First Posted Date
- 2012-11-28
- Last Posted Date
- 2015-09-23
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 90
- Registration Number
- NCT01734824
- Locations
- 🇦🇹
Medical University Vienna - St. Vincent Hospital, Vienna, Austria
Effects of Denosumab on Periprosthetic Bone After Total Hip Arthroplasty
- First Posted Date
- 2012-06-28
- Last Posted Date
- 2017-04-05
- Lead Sponsor
- Hans Mallmin
- Target Recruit Count
- 64
- Registration Number
- NCT01630941
- Locations
- 🇸🇪
Department of Orthopedics, Uppsala, Sweden
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.